Finance

Lists
KLBF:IDX
Kalbe Farma Tbk PT
IDR 785,00
+1,29%
(+10,00) 1D
9 Okt., 16:14:38 GMT+7  ·   IDR
All symbols
SymbolPriceChange% Change
Generating top insights for KLBF...
Open
IDR 780
High
IDR 795
Low
IDR 770
Mkt. cap
36,75 bn
Avg. vol.
65,83 m
Volume
56,56 m
Dividend
2,55%
Quarterly dividend
IDR 5
Ex-dividend date
04 Jun. 2026
P/E ratio
9,87
52-wk high
IDR 1 345
52-wk low
IDR 630
EPS
IDR 80
Shares outstanding
46,81 mjd
No. of employees
13 k
Open
IDR 780
High
IDR 795
Low
IDR 770
Mkt. cap
36,75 bn
Avg. vol.
65,83 m
Volume
56,56 m
Dividend
2,55%
Quarterly dividend
IDR 5
Ex-dividend date
04 Jun. 2026
P/E ratio
9,87
52-wk high
IDR 1 345
52-wk low
IDR 630
EPS
IDR 80
Shares outstanding
46,81 mjd
No. of employees
13 k
News stories
From web sources and news partners
Profile
PT Kalbe Farma Tbk, or simply known as Kalbe, is an Indonesian pharmaceutical, healthcare and nutrition company established in 1966. The company has expanded by strategic acquisitions of pharmaceutical companies, becoming an integrated consumer health and nutrition enterprise. The Kalbe Group has brands in the prescription drugs, OTC drugs, energy drink and nutrition products, with a distribution arm that reaches over one million outlets. Notably, the company produces misoprostol, a drug which is used to treat stomach ulcers but is also widely used in Indonesia as an illegal abortifacient. Company brands in healthcare and pharmaceutical segments include Promag, Mixagrip, Woods, Komix, Diabetasol, Prenagen, Extra Joss and Fitbar. Kalbe is the largest publicly listed pharmaceutical company in Southeast Asia with around US$5 billion in market capitalization and revenues of over Rp 15 trillion. The name "Kalbe" is a syllabic abbreviation of its founder's name: Khouw Lip Boen. Wikipedia
About Kalbe Farma Tbk PT
CEO-
Employees12,8 k
Founded10 Sep. 1966
Headquarters-
SectorPharmaceutical industry
Last report
28 Jul. 2026
Fiscal period
Q2 2026
IDR 19,68 / IDR 20,14
-2,28%miss
Revenue / Est. (IDR)
9,80 bn / -
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in IDR
Loading Previous Earnings...
Revenue
Net income
All values in IDR
Sep. 2025
Des. 2025
Mrt. 2026
Jun. 2026
Revenue
8,91 bn
9,34 bn
9,68 bn
9,80 bn
Cost of goods sold
5,46 bn
5,92 bn
6,02 bn
6,25 bn
Cost of revenue
5,46 bn
5,92 bn
6,02 bn
6,25 bn
Research and development expenses
98,31 mjd
160,88 mjd
113,14 mjd
122,60 mjd
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
2,51 bn
1,95 bn
2,23 bn
2,27 bn
Operating expense
2,60 bn
2,14 bn
2,33 bn
2,39 bn
Total operating expenses
8,06 bn
8,05 bn
8,36 bn
8,64 bn
Operating income
851,77 mjd
1,28 bn
1,32 bn
1,16 bn
Other non operating income
-3,78 mjd
-4,17 mjd
-3,63 mjd
-3,74 mjd
EBT including unusual items
877,87 mjd
1,30 bn
1,36 bn
1,19 bn
EBT excluding unusual items
888,55 mjd
1,30 bn
1,36 bn
1,18 bn
Income tax expense
211,19 mjd
252,81 mjd
303,84 mjd
271,57 mjd
Effective tax rate
24,06%
19,41%
22,40%
22,80%
Other operating expenses
-7,23 mjd
31,35 mjd
-10,02 mjd
2,13 mjd
Net income
656,41 mjd
1,03 bn
1,03 bn
890,54 mjd
Net profit margin
7,37%
11,07%
10,63%
9,09%
Earnings per share
14,44
22,72
22,74
19,68
Interest and investment income
41,31 mjd
40,43 mjd
32,07 mjd
43,61 mjd
Interest expense
-9,69 mjd
-5,77 mjd
-4,61 mjd
-6,78 mjd
Net interest expenses
31,62 mjd
34,66 mjd
27,46 mjd
36,83 mjd
Depreciation and amortization charges
-
-
-
-
EBITDA
1,05 bn
1,45 bn
1,51 bn
1,20 bn
Gain or loss from assets sale
-
-
-
-
AI content may include mistakes. Learn more
Google-programme